TGFB1 and idiopathic pulmonary fibrosis: In our assays, nintedanib, one of two currently approved drugs for IPF, inhibited TGF–β1–induced myofibroblast formation in the HCA, inhibited impedance changes, and attenuated α–SMA and COL1 increase in IPQA (Table 3).